Rapid Results - Latest quarterly results analysis.

Pharmaceuticals company Fermenta Biotech announced Q4FY26 & FY26 results Standalone Financial Highlights: Quarterly Income: The company reported a Total Income of Rs 11,597.51 lakh in Q4FY26, representing a decrease of 1.44% compared to Rs 11,767.39 lakh in Q3FY26 (QoQ) and a decrease of 7.90% from Rs 12,592.09 lakh in Q4FY25 (YoY). Quarterly Revenue: Revenue from operations for Q4FY26 stood at Rs 10,987.63 lakh, a decline of 3.82% QoQ from Rs 11,424.25 lakh and a decline of 9.97% YoY from Rs 12,203.79 lakh. Quarterly Profit: Net Profit for Q4FY26 was Rs 2,157.28 lakh, showing a significant growth of 83.45% from Rs 1,175.92 lakh in Q3FY26. However, it decreased by 26.40% compared to Rs 2,931.12 lakh in Q4FY25. Annual Income: For FY26, the company achieved a Total Income of Rs 47,415.16 lakh, up 7.22% from Rs 44,220.95 lakh in FY25. Annual Revenue: Revenue from operations for FY26 reached Rs 45,025.27 lakh, a growth of 4.58% over Rs 43,053.17 lakh in FY25. Annual Profit: Standalone Net Profit for FY26 was Rs 6,428.36 lakh, representing a marginal decrease of 4.93% compared to Rs 6,761.54 lakh in FY25. Earnings Per Share (EPS): Standalone Basic EPS for FY26 stood at Rs 22.13 compared to Rs 23.18 in FY25. Consolidated Financial Highlights: Quarterly Income: Consolidated Total Income for Q4FY26 was Rs 12,664.73 lakh, a decrease of 9.85% from Rs 14,047.77 lakh in Q3FY26 (QoQ) and a decline of 11.89% from Rs 14,374.20 lakh in Q4FY25 (YoY). Quarterly Revenue: Revenue from operations for Q4FY26 was Rs 12,158.34 lakh, down 11.50% QoQ from Rs 13,739.06 lakh and down 13.06% YoY from Rs 13,984.81 lakh. Quarterly Profit: Consolidated Net Profit for Q4FY26 stood at Rs 1,860.03 lakh, a QoQ increase of 54.70% from Rs 1,202.31 lakh, but a YoY decline of 44.18% from Rs 3,332.34 lakh. Annual Income: Consolidated Total Income for FY26 was Rs 54,781.46 lakh, reflecting an increase of 13.82% compared to Rs 48,129.58 lakh in FY25. Annual Revenue: Annual Consolidated Revenue from operations reached Rs 52,542.94 lakh in FY26, up 11.92% from Rs 46,947.73 lakh in FY25. Annual Profit: Consolidated Net Profit for FY26 was Rs 7,025.43 lakh, a decrease of 8.05% compared to Rs 7,640.28 lakh in FY25. Earnings Per Share (EPS): Consolidated Basic EPS for FY26 stood at Rs 24.70 compared to Rs 26.35 in FY25. Dividend: The Board has recommended a final equity dividend of Rs 3.75 per equity share of Rs 5 each (75%) for the financial year ended March 31, 2026. Business Highlights: Segment Performance: Bulk drugs/chemicals: This segment contributed Rs 51,472.17 lakh to the total revenue in FY26, showing a growth of 28.52% over Rs 40,048.76 lakh in FY25. Property: Revenue from this segment was Rs 951.27 lakh in FY26, a sharp decline compared to Rs 5,440.18 lakh in FY25. Exceptional Items: The company recorded an exceptional item (expense) of Rs 798 lakh in the consolidated results for FY26 (standalone Rs 444 lakh). This pertains to an impairment loss for certain non-operational plants located in India and a subsidiary plant in Malaysia. Asset Monetization: During FY26, the company sold parts of its freehold land at Village Takave and commercial property in Ceejay House, Worli, Mumbai. Standalone revenue under "Other Income" from these property sales amounted to Rs 856.23 lakh for FY26. Prashant Nagre, Managing Director, said: “The turnaround of FY25 was further confirmed in FY26. While growth of revenue, excluding that from real estate unlocking, was 57% in FY25 over FY24, in FY26 revenue growth was 26% over FY25. On the underlying operating business, as explained above, with that one-time inflow stripped from both periods, PAT quality has in fact strengthened over the year. Our FY26 EBITDA (excluding real estate) demonstrates robust operational leverage— as it surpassed our FY25 EBITDA by 44%. Our sustained efforts over the years in expanding the enzymes portfolio and their application & customer base have started yielding initial results. We are confident of continuing to expand & grow this portfolio. While human nutrition volumes grew by 43% in FY25 over FY24, we have further seen the volumes grow by 21% in FY26 over FY25. Our sustained volume momentum, combined with improving margins, positions Fermenta well for continued value creation. We remain focused on scaling our core human nutrition business while exploring strategic opportunities. FY26 delivered the foundational layer for our two flagship product introductions — the granted Indian process patent for plant-based Vitamin D3 secured in September 2025, the EDQM Certificate of Suitability for the Vitamin D3 100 SD premix, and the Letter of Approval from the Global Alliance for Improved Nutrition. Commercial launches of VITADEE Green and Vitamin D3 100 SD are now sequenced for FY27, in line with the patent-certification-capacity-launch sequence appropriate to pharmaceutical-grade chemistry. Our ongoing capex at Dahej will establish commercial-scale production of plant-based Vitamin D3 (for which we hold Indian patent protection) alongside new Vitamin D3 derivatives. This strengthens our position as one of the world's leading fully integrated Vitamin D3 manufacturers. Result PDF

Latest Rapid Results